MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells
- 468 Downloads
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancies. Platinum-based chemotherapy is the first-line treatment for the advanced ovarian cancer, but resistance to cisplatin remains a major obstacle to successful treatment. MicroRNAs (miRNAs) are a class of non-coding RNAs that play important roles in disease processes, including the development of drug resistance. In this study, we found miR-449a were significantly downregulated in the cisplatin-resistant ovarian cell lines SKOV3/DDP and A2780/DDP, compared with their sensitive parent line SKOV3 and A2780, respectively. The overexpression of miR-449a increased cisplatin sensitivity of SKOV3/DDP and A2780/DDP cells by inhibiting proliferation and promoting apoptosis. The luciferase assay confirmed that miR-449a functioned through suppressing NOTCH1 directly. Concordantly, BALB/c nude mice that were injected intraperitoneally with SKOV3/DDP cells transfected with miR-449a mimics exhibited enhanced cisplatin sensitivity in vivo. Taken together, these results suggest that the ectopic expression of miR-449a may be a promising therapeutic strategy for the management of cisplatin resistance in ovarian cancer.
KeywordsOvarian cancer MicroRNA-449a Cisplatin resistance NOTCH1
- 2.Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in china cancer registries, 2009. Chin J Cancer Res = Chung-Kuo Yen Cheng Yen Chiu. 2013;25:10–21.Google Scholar
- 14.Kong F, Sun C, Wang Z, Han L, Weng D, Lu Y, et al. miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic bcl-2 antagonist killer 1. J Huazhong Univ Sci Technol Med Sci = Hua zhong Ke Ji Da Xue Xue Bao Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao Yixue Yingdewen Ban. 2011;31:543–9.CrossRefGoogle Scholar
- 15.Wu H, Xiao Z, Zhang H, Wang K, Liu W, Hao Q. miR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3. Anti-cancer Drugs 2014.Google Scholar